Instinct Bio equity funding plan could provide up to $150 million

Instinct Bio has lined up a proposed equity funding facility that could let the Nasdaq-listed biotech, trading under BIOT, sell up to $150 million of common stock over three years. For retail investors, the setup offers a potential capital source for growth in regenerative medicine, while also raising the usual concern that new share sales can dilute existing holders.

The company announced an indicative term sheet for an equity purchase facility, a financing structure that gives a public company the ability to sell shares over time instead of raising all the money in one transaction. The arrangement is proposed, so it is not the same as cash already received.

Under the term sheet, Instinct Bio would have the right, but not the obligation, to direct purchases of its common stock from time to time. Any sales would be subject to limits, conditions and regulatory requirements, according to the company.

How does Instinct Bio's equity purchase facility work?

The purchase price for shares sold through the facility would generally be tied to the volume-weighted average price, or VWAP, of BIOT stock on the purchase date, minus a specified discount. VWAP is the average price of a stock during a trading period, weighted by how many shares traded at each price, so it is often used as a benchmark for market-based stock sales.

This kind of facility can give a company more control over timing than a one-time stock offering. Instinct Bio could choose when to tap the facility, if final documents are signed and the required conditions are met. The trade-off for shareholders is dilution risk: if the company issues more common stock, each existing share represents a smaller ownership slice unless the company’s value grows enough to offset that effect.

The proposed BIOT equity purchase facility follows Instinct Bio’s recent business combination with Relativity Acquisition Corp. Instinct Bio said proceeds would be used to advance its regenerative medicine platform, fund working capital and pursue strategic acquisitions tied to its longevity-focused business.

Instinct Bio describes itself as a biotechnology company focused on regenerative medicine, longevity-related technologies and advanced therapeutic platforms. Regenerative medicine generally refers to approaches aimed at repairing, replacing or restoring cells, tissues or biological function, a field that can require steady capital because development timelines are often long.

Chief Executive Officer Tomoki Nagano said the proposed facility would add financial flexibility as the company works on its strategic goals. He said the structure is intended to let Instinct Bio access capital when it sees an opportunity while managing financing needs over time.

The company also cautioned that there is no assurance definitive transaction documents will be completed, that the facility’s conditions will be satisfied or that Instinct Bio will receive any funding through the arrangement. Its forward-looking statements also cite risks tied to market conditions, regulatory requirements, competition, financing access, intellectual property and its recent business combination.